Literature DB >> 29198280

Alzheimer's Disease: Past, Present, and Future.

Mark W Bondi1, Emily C Edmonds1, David P Salmon2.   

Abstract

Although dementia has been described in ancient texts over many centuries (e.g., "Be kind to your father, even if his mind fail him." - Old Testament: Sirach 3:12), our knowledge of its underlying causes is little more than a century old. Alzheimer published his now famous case study only 110 years ago, and our modern understanding of the disease that bears his name, and its neuropsychological consequences, really only began to accelerate in the 1980s. Since then we have witnessed an explosion of basic and translational research into the causes, characterizations, and possible treatments for Alzheimer's disease (AD) and other dementias. We review this lineage of work beginning with Alzheimer's own writings and drawings, then jump to the modern era beginning in the 1970s and early 1980s and provide a sampling of neuropsychological and other contextual work from each ensuing decade. During the 1980s our field began its foundational studies of profiling the neuropsychological deficits associated with AD and its differentiation from other dementias (e.g., cortical vs. subcortical dementias). The 1990s continued these efforts and began to identify the specific cognitive mechanisms affected by various neuropathologic substrates. The 2000s ushered in a focus on the study of prodromal stages of neurodegenerative disease before the full-blown dementia syndrome (i.e., mild cognitive impairment). The current decade has seen the rise of imaging and other biomarkers to characterize preclinical disease before the development of significant cognitive decline. Finally, we suggest future directions and predictions for dementia-related research and potential therapeutic interventions. (JINS, 2017, 23, 818-831).

Entities:  

Keywords:  Alzheimer’s disease; Biomarkers; Clinical trials; Cognition; Mild cognitive impairment; Neuroimaging; Neuropsychology; Neuroscience

Mesh:

Year:  2017        PMID: 29198280      PMCID: PMC5830188          DOI: 10.1017/S135561771700100X

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  102 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  Mild cognitive impairment as a clinical entity and treatment target.

Authors:  Ronald C Petersen; John C Morris
Journal:  Arch Neurol       Date:  2005-07

3.  Editorial: The prevalence and malignancy of Alzheimer disease. A major killer.

Authors:  R Katzman
Journal:  Arch Neurol       Date:  1976-04

4.  Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors.

Authors:  Emily C Edmonds; Lisa Delano-Wood; Lindsay R Clark; Amy J Jak; Daniel A Nation; Carrie R McDonald; David J Libon; Rhoda Au; Douglas Galasko; David P Salmon; Mark W Bondi
Journal:  Alzheimers Dement       Date:  2014-05-22       Impact factor: 21.566

5.  Vitamin E and donepezil for the treatment of mild cognitive impairment.

Authors:  Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal
Journal:  N Engl J Med       Date:  2005-04-13       Impact factor: 91.245

6.  Impaired recall and the memory disturbance in presenile dementia.

Authors:  E Miller
Journal:  Br J Soc Clin Psychol       Date:  1975-02

7.  The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease.

Authors:  David A Drachman
Journal:  Alzheimers Dement       Date:  2014-02-28       Impact factor: 21.566

8.  Major changes in psychiatric nomenclature. Reconciling existing psychiatric medical records with the new American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders.

Authors:  P T Wilson; R L Spitzer
Journal:  Hosp Community Psychiatry       Date:  1968-06

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 10.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

View more
  86 in total

1.  Neuropsychological latent classes at enrollment and postmortem neuropathology.

Authors:  Andrea R Zammit; Charles B Hall; David A Bennett; Ali Ezzati; Mindy J Katz; Graciela Muniz-Terrera; Richard B Lipton
Journal:  Alzheimers Dement       Date:  2019-08-13       Impact factor: 21.566

2.  Neuroprotective Effects of 2-Substituted 1, 3-Selenazole Amide Derivatives on Amyloid-Beta-Induced Toxicity in a Transgenic Caenorhabditis Elegans Model of Alzheimer's Disease.

Authors:  Huiying Wang; Yuandong Yue; Haifeng Zhao; Hao Wu; Kai Jiang; Shuang Li; Meihua Zhao; Feng Lin
Journal:  Neurotox Res       Date:  2021-01-05       Impact factor: 3.911

3.  Polymorphism rs11867353 of Tyrosine Kinase Non-Receptor 1 (TNK1) Gene Is a Novel Genetic Marker for Alzheimer's Disease.

Authors:  Tomáš Zeman; Vladimir J Balcar; Kamila Cahová; Jana Janoutová; Vladimír Janout; Jan Lochman; Omar Šerý
Journal:  Mol Neurobiol       Date:  2020-10-18       Impact factor: 5.590

4.  Protective Effects of Co-administration of Zinc and Selenium Against Streptozotocin-Induced Alzheimer's Disease: Behavioral, Mitochondrial Oxidative Stress, and GPR39 Expression Alterations in Rats.

Authors:  Yaghoob Farbood; Alireza Sarkaki; Masoud Mahdavinia; Ata Ghadiri; Ali Teimoori; Faezeh Seif; Mohammad Amin Dehghani; Seyedeh Parisa Navabi
Journal:  Neurotox Res       Date:  2020-06-05       Impact factor: 3.911

Review 5.  Late-onset Alzheimer Disease.

Authors:  Gil D Rabinovici
Journal:  Continuum (Minneap Minn)       Date:  2019-02

6.  MiR-539-5p Decreases amyloid β-protein production, hyperphosphorylation of Tau and Memory Impairment by Regulating PI3K/Akt/GSK-3β Pathways in APP/PS1 Double Transgenic Mice.

Authors:  Yushu Jiang; Yuan Zhang; Li Su
Journal:  Neurotox Res       Date:  2020-05-15       Impact factor: 3.911

Review 7.  Specific Basal Forebrain-Cortical Cholinergic Circuits Coordinate Cognitive Operations.

Authors:  Laszlo Záborszky; Peter Gombkoto; Peter Varsanyi; Matthew R Gielow; Gina Poe; Lorna W Role; Mala Ananth; Prithviraj Rajebhosale; David A Talmage; Michael E Hasselmo; Holger Dannenberg; Victor H Minces; Andrea A Chiba
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

Review 8.  A Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association.

Authors:  Ronald M Lazar; Virginia J Howard; Walter N Kernan; Hugo J Aparicio; Deborah A Levine; Anthony J Viera; Lori C Jordan; David L Nyenhuis; Katherine L Possin; Farzaneh A Sorond; Carole L White
Journal:  Stroke       Date:  2021-03-15       Impact factor: 7.914

9.  The Application of Convolutional Neural Network Model in Diagnosis and Nursing of MR Imaging in Alzheimer's Disease.

Authors:  Xiaoxiao Chen; Linghui Li; Ashutosh Sharma; Gaurav Dhiman; S Vimal
Journal:  Interdiscip Sci       Date:  2021-07-05       Impact factor: 2.233

10.  Lacidipine Prevents Scopolamine-Induced Memory Impairment by Reducing Brain Oxido-nitrosative Stress in Mice.

Authors:  Kunal Khurana; Manish Kumar; Nitin Bansal
Journal:  Neurotox Res       Date:  2021-03-15       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.